Brain

NAV's Bold Move: Pioneering Structured Investment Products in the DeFi Arena

Retrieved on: 
Thursday, March 7, 2024

Through a strategic partnership combining Digits Capital's market expertise with Open Hedge's technological acumen, NAV delivers sophisticated, quantitatively driven investment products.

Key Points: 
  • Through a strategic partnership combining Digits Capital's market expertise with Open Hedge's technological acumen, NAV delivers sophisticated, quantitatively driven investment products.
  • NAV's offerings are predicated on its Structured Investment Products (SIPs), which contain an assortment of Ecosystem specific strategies, customised to particular blockchain environments, and delta neutral quantitative based strategies like NAV’s Funding Arbitrage SIP.
  • With superior analytics and strategic automation, this cooperation makes NAV a pioneer in high-yield DeFi products.
  • Regulatory compliance and inclusiveness as a BVI-registered hedge fund are the fundamental pillars of NAV's approach to DeFi investments as the company works to expand its range of Structured Investment Products.

NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

Retrieved on: 
Thursday, March 7, 2024

IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.

Key Points: 
  • IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.
  • In addition, reductions in neurodegenerative markers were also observed following oral dosing of NT-0796, including NfL and soluble TREM (sTREM2).
  • The correlation between Parkinson’s disease and neuroinflammation is well-documented, with alpha-synuclein fibrils triggering microglial NLRP3 activation, leading to neuroinflammation and subsequent neurodegeneration.
  • This is the inaugural demonstration of an NLRP3 inhibitor’s potential to not only address Parkinson’s disease but also offer a broader impact on neurodegenerative diseases.

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

Retrieved on: 
Wednesday, March 6, 2024

In addition, exploratory clinical endpoints improved compared to baseline assessments in both cohorts, with participants in the high dose cohort showing greater improvement than those in the low dose cohort.

Key Points: 
  • In addition, exploratory clinical endpoints improved compared to baseline assessments in both cohorts, with participants in the high dose cohort showing greater improvement than those in the low dose cohort.
  • Time spent in the “OFF” state showed a mean decrease of 2.7 hours after 18 months.
  • “We are excited to see the continued positive trends in the data from bemdaneprocel’s phase I trial at 18 months,” said Ahmed Enayetallah, Senior Vice President and Head of Development at BlueRock Therapeutics.
  • “There are good reasons to be optimistic about these early data, and we are excited to move to phase II later this year.”

Ibogaine By David Dardashti To Explore Glial Cells Through EEG With Computer Tomography

Retrieved on: 
Tuesday, March 5, 2024

Ibogaine By David Dardashti hopes to advance ibogaine research, with major projects involving a cross-analytical approach of EEG with computer tomography.

Key Points: 
  • Ibogaine By David Dardashti hopes to advance ibogaine research, with major projects involving a cross-analytical approach of EEG with computer tomography.
  • By using EEG and computer tomography, the Ibogaine By David Dardashti clinic will be able to detect any difference in glial cell production after treatment.
  • David Dardashti, founder of the Ibogaine By David Dardashti clinic, comments, “We are extremely excited about the potential this project could bring to the field of ibogaine healing and electrodynamic understanding of glial cell production in the brain.
  • This could be a major turning point in ibogaine therapy, with greater understanding of how ibogaine affects the brain in real time.”
    The Ibogaine By David Dardashti clinic is utilizing EEG and computer tomography to measure changes in brain growth and glial cell production with the goal of gaining greater understanding of ibogaine healing and electrodynamic understanding of the brain.

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

Retrieved on: 
Tuesday, March 5, 2024

The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.

Key Points: 
  • The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.
  • Philanthropy is central to the work of Lady Gaga and Michael Polansky, Sean Parker and Alexandra Parker.
  • At the event in Malibu, CLINUVEL announced the Photomedicine Foundation, which will count Mr Polansky as a trustee.
  • CLINUVEL is grateful to have their support as we translate our pharmaceutical technology into PhotoCosmetics and give back to underserved communities.

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Retrieved on: 
Tuesday, March 5, 2024

BALTIMORE, March 05, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

Key Points: 
  • A board-certified internist and anesthesiologist, Dr. Roizen has been instrumental in the development of many successful ventures.
  • He also served 16 years on Food and Drug Administration (FDA) advisory committee and chaired one for two years.
  • Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir, stated, “Telomir's groundbreaking work has captured the attention and imagination of the industry.
  • We look forward to his continued contributions to our efforts.”
    To be included in the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

Detection of Suicide-Related Emergencies Among Children Using Real-World Clinical Data: A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Monday, March 4, 2024

The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “ Detection of Suicide-Related Emergencies Among Children Using Real-World Clinical Data ” on Tuesday, March 12, 2024, at 2:00 pm ET to discuss how we can improve prediction and prevention of youth suicide.

Key Points: 
  • The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “ Detection of Suicide-Related Emergencies Among Children Using Real-World Clinical Data ” on Tuesday, March 12, 2024, at 2:00 pm ET to discuss how we can improve prediction and prevention of youth suicide.
  • Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds will be the webinar host.
  • Register today at BBRFoundation.org
    Suicide is a national and international public health priority, and suicidal behavior among children is common, costly, and preventable.
  • Systematic, accurate, and equitable detection of children who exhibit suicidal thoughts and behaviors to medical personnel is challenging.

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
Monday, March 4, 2024

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).